Genelux Case Report Details 16.7-Month PFS in Platinum-Relapsed SCLC After Systemic Olvi-Vec Plus Platinum Rechallenge
核心洞察
A platinum-relapsed small cell lung cancer (搜索) patient achieved 16.7 months of progression-free survival after systemic Olvi-Vec plus platinum rechallenge, exceeding her prior first-line PFS of 14.3 months.
The case report, published in Frontiers in Oncology, describes an 84.6% reduction in target lesion size, surpassing the reduction seen after first-line platinum and etoposide therapy.
Findings come from the Phase 1b/2 OLVI-VEC-202-SCLC trial (NCT07136285), an open-label study run in China by licensing partner Newsoara HYK Biopharmaceuticals (搜索).
Genelux Corporation has published a case report describing a deep and durable response in a platinum-relapsed small cell lung cancer (搜索) (SCLC) patient treated with systemically delivered Olvi-Vec followed by platinum rechallenge, with the patient achieving 16.7 months of progression-free survival (PFS) — longer than the 14.3 months she achieved after platinum-based first-line therapy.
The report, published in Frontiers in Oncology, a peer-reviewed journal published by Frontiers Media S.A., comes from the ongoing Phase 1b dose escalation portion of the Phase 1b/2 OLVI-VEC-202-SCLC trial (NCT07136285). The trial is an open-label study evaluating a single intravenous cycle with multiple doses of Olvi-Vec administered in combination with platinum and etoposide chemotherapy in patients with platinum-relapsed or platinum-refractory SCLC after failing previous first-line treatment with platinum and etoposide. It is being conducted in China by Genelux's licensing partner, Newsoara HYK Biopharmaceuticals (搜索) Co. (Shanghai), Ltd.
Case Details and Response Magnitude
According to the published report, the patient was a 58-year-old woman previously treated for extensive stage SCLC with four cycles of frontline standard treatment with platinum and etoposide, followed by radiotherapy to the lung and prophylactic brain radiotherapy. That first-line regimen produced a 14.3-month PFS and a duration of response (DOR) of 13.0 months.
Following treatment with Olvi-Vec and platinum rechallenge, the patient achieved 16.7 months of PFS, exceeding the PFS achieved after platinum-based first-line therapy. The patient also achieved an 84.6% reduction in target lesion size, as previously reported by Genelux, which exceeded the reduction achieved following first-line therapy.
"This compelling case published in Frontiers in Oncology provides clinically relevant evidence that strengthens our commitment to evaluating systemic (intravenous) administration of Olvi-Vec in combination with platinum-based chemotherapy and potentially other treatment regimens," said Thomas Zindrick, President, CEO, and Chairman of Genelux. "We are encouraged by the consistency between our preclinical and clinical data with Olvi-Vec-primed immunochemotherapy which supports a mechanism of action by which Olvi-Vec-mediated changes to the tumor microenvironment may enhance responsiveness to therapies in both first-line and recurrent settings."
Mechanism and Translational Rationale
The findings support the potential of systemically administered Olvi-Vec to drive anti-tumor activity and enhance responsiveness to platinum-based chemotherapy in difficult-to-treat cancers. Genelux's approach centers on tumor-priming immunotherapy, in which Olvi-Vec-mediated changes to the tumor microenvironment are hypothesized to sensitize tumors to platinum-based chemotherapy.
Supporting translational evidence was published in June 2026 in Gynecologic Oncology Reports, a peer-reviewed journal published by Elsevier. Those analyses, from the Phase 1b/2 VIRO-15 trial in heavily pre-treated ovarian cancer patients, demonstrated immune activation, remodeling of the tumor microenvironment, and gene expression changes consistent with platinum sensitization following Olvi-Vec treatment.
Systemic Lung Cancer Development Programs
Genelux is advancing two ongoing systemic Olvi-Vec lung cancer trials, expanding the platform beyond intraperitoneal delivery into a broader range of solid tumor types. Data from dose-escalation cohorts in these studies are designed to generate the clinical evidence needed to guide selection of a recommended systemic dose for subsequent development in lung cancer and for future development in additional systemic indications.
The Phase 1b/2 OLVI-VEC-SCLC-202 study (NCT07136285) is evaluating Olvi-Vec in combination with platinum and etoposide chemotherapy in SCLC patients with platinum-resistant or relapsed disease after failing previous treatment, including frontline platinum and etoposide chemotherapy.
The Phase 2 VIRO-25 study (NCT06463665) is assessing Olvi-Vec in combination with platinum-based chemotherapy and an immune checkpoint inhibitor (ICI) in patients with advanced or metastatic recurrent non-small-cell lung cancer (搜索) (NSCLC) who failed standard frontline treatment of platinum chemotherapy and an ICI. The trial is being conducted in the United States and is designed to extend Olvi-Vec's tumor-priming approach into NSCLC.
Additional dose-finding updates from both the SCLC Phase 1b/2 and NSCLC Phase 2 VIRO-25 trials are expected in 2026, aligning with the company's strategy to optimize a systemic dosing regimen and inform future registrational development.
Ovarian Cancer Registrational Program
Genelux continues to advance Olvi-Vec toward potential registration for platinum-resistant/refractory ovarian cancer (搜索) (PRROC), a setting defined by limited treatment options. Ovarian cancer is the fifth leading cause of cancer-related death among women, and more than 70% of patients diagnosed with ovarian cancer in the United States will not respond to or will relapse after frontline platinum-based therapy, according to the NIH Ovarian Cancer Fact Sheet 2022.
Olvi-Vec's intraperitoneal administration is designed to deliver high, localized dosing within the peritoneal cavity to drive anti-tumor activity and resensitize tumors to platinum-based chemotherapy.
OnPrime/GOG-3076 (NCT05281471) is an ongoing multi-center, randomized, open-label Phase 3 registrational trial being conducted at sites across the United States, with topline data anticipated in the second half of 2026. The trial is evaluating Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab against an active comparator arm of physician's choice of chemotherapy and bevacizumab in women with PRROC, including fallopian tube and primary peritoneal cancers.
Financial Position
Genelux reported cash, cash equivalents, marketable securities and restricted cash of $18.7 million as of June 30, 2026, which the company expects will fund operations into the first quarter of 2027. Research and development expenses were $6.5 million for the three months ended June 30, 2026, compared with $4.8 million for the same period in 2025, an increase driven primarily by clinical and regulatory expenses relating to increased clinical trial costs associated with the Phase 3 OnPrime/GOG-3076 registration trial. General and administrative expenses were $3.1 million, compared with $3.0 million a year earlier. Net loss was $9.5 million, or $0.21 per share, compared with $7.5 million, or $0.20 per share, for the same period in 2025.
Genelux is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic immunotherapies for patients with aggressive and/or difficult-to-treat tumor types. The core of its discovery and development efforts revolves around its proprietary CHOICE platform, from which it has developed a library of isolated and engineered oncolytic vaccinia virus (搜索) immunotherapeutic product candidates, including Olvi-Vec.